New cancer drug targets immune system in early human trial
NCT ID NCT05597839
Summary
This was an early-stage study to test a new drug called DF9001 in people with advanced solid tumors that have spread, returned, or cannot be removed by surgery. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that the drug could help shrink tumors, either by itself or combined with another immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR Kansas City
Kansas City, Missouri, 64114, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Rutgers
New Brunswick, New Jersey, 08903, United States
-
UC Irvine Medical Center
Irvine, California, 92617, United States
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Louisville Hospital
Louisville, Kentucky, 40202, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.